The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by KFDA (Korea Food and drug administration)

Inclusion Criteria:

• Signed and dated informed consent
• Women after menarche and before menopause
• Women requesting contraception or Women diagnosed by a physician as having HMB due to non-organic cause who are also requesting contraception
• Women who are prescribed Qlaira® for the first time, during the study period

Exclusion Criteria:

- All contraindications according to the local marketing authorization have to be considered.

Generally healthy women after menarche and before menopause desiring contraception with or without HMB will be recruited who are determined to start Qlaira